185 related articles for article (PubMed ID: 26893303)
1. Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.
Dallas S; Salphati L; Gomez-Zepeda D; Wanek T; Chen L; Chu X; Kunta J; Mezler M; Menet MC; Chasseigneaux S; Declèves X; Langer O; Pierre E; DiLoreto K; Hoft C; Laplanche L; Pang J; Pereira T; Andonian C; Simic D; Rode A; Yabut J; Zhang X; Scheer N
Mol Pharmacol; 2016 May; 89(5):492-504. PubMed ID: 26893303
[TBL] [Abstract][Full Text] [Related]
2. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
3. Role of the breast cancer resistance protein (ABCG2) in drug transport.
Mao Q; Unadkat JD
AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.
Zhao R; Raub TJ; Sawada GA; Kasper SC; Bacon JA; Bridges AS; Pollack GM
Drug Metab Dispos; 2009 Jun; 37(6):1251-8. PubMed ID: 19273529
[TBL] [Abstract][Full Text] [Related]
5. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
Hoque MT; Shah A; More V; Miller DS; Bendayan R
J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
[TBL] [Abstract][Full Text] [Related]
6. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.
Poller B; Drewe J; Krähenbühl S; Huwyler J; Gutmann H
Cell Mol Neurobiol; 2010 Jan; 30(1):63-70. PubMed ID: 19629677
[TBL] [Abstract][Full Text] [Related]
7. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
8. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions.
Xia CQ; Yang JJ; Gan LS
Expert Opin Drug Metab Toxicol; 2005 Dec; 1(4):595-611. PubMed ID: 16863427
[TBL] [Abstract][Full Text] [Related]
11. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
[TBL] [Abstract][Full Text] [Related]
12. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).
Ni Z; Bikadi Z; Rosenberg MF; Mao Q
Curr Drug Metab; 2010 Sep; 11(7):603-17. PubMed ID: 20812902
[TBL] [Abstract][Full Text] [Related]
13. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
[TBL] [Abstract][Full Text] [Related]
14. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
15. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
[TBL] [Abstract][Full Text] [Related]
16. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier.
Sun A; Wang J
Pharm Res; 2023 Nov; 40(11):2667-2675. PubMed ID: 37704894
[TBL] [Abstract][Full Text] [Related]
17. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway.
Hamdan AM; Koyanagi S; Wada E; Kusunose N; Murakami Y; Matsunaga N; Ohdo S
J Biol Chem; 2012 May; 287(21):17224-17231. PubMed ID: 22396548
[TBL] [Abstract][Full Text] [Related]
18. Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1.
Dreiseitel A; Oosterhuis B; Vukman KV; Schreier P; Oehme A; Locher S; Hajak G; Sand PG
Br J Pharmacol; 2009 Dec; 158(8):1942-50. PubMed ID: 19922539
[TBL] [Abstract][Full Text] [Related]
19. Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.
Bircsak KM; Aleksunes LM
Curr Drug Metab; 2015; 16(2):124-40. PubMed ID: 26179608
[TBL] [Abstract][Full Text] [Related]
20. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
